Mankind Pharma Limited
↗New Delhi, India
Mankind Pharma is India's fourth-largest pharmaceutical company by domestic sales, headquartered in New Delhi. Founded in 1995 by brothers Ramesh C. Juneja and Rajeev Juneja with seed capital of ₹5 million, the company has grown into a multinational pharmaceutical and healthcare products manufacturer. With 30 manufacturing facilities and 6 R&D centers across India, Mankind operates across multiple therapeutic areas including antibiotics, gastrointestinal, cardiovascular, dermatology, and women's health. The company derives 97% of revenue from the Indian market and is known for consumer healthcare brands like Manforce (condoms), Prega News (pregnancy test kits), and Unwanted-72 (emergency contraception). In 2024, Mankind completed a landmark acquisition of Bharat Serums and Vaccines for ₹13,630 crore, significantly expanding its portfolio in women's health, fertility drugs, and critical care products.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Generic Pharmaceuticals & Consumer Healthcare
SIZE & FINANCIALS
Employees:10000+
Revenue:₹12,000-13,000 crore (~$1.4-1.6B USD)
Founded:1995
Ownership:public
Status:operating
FUNDING
Stage:Public Company (IPO: April 2023)
Total Raised:₹4,326 crore from IPO (2023)
Investors:Advent International (previously held BSV stake, divested in acquisition), QIP investors (2024-2025)
STOCK
Exchange:NSE
Ticker:MANKIND
Market Cap:₹893.56 billion (~$10.7 billion USD)
PIPELINE
Stage:Commercial & Clinical
Lead Drug Stage:ACM-001.1 in Phase 2b/3 for cancer cachexia
Modalities:Small molecule, Tablets, Capsules, Injectable (ampoules, vials), Syrups, Soft and hard gels, Creams and ointments, Eye drops, Vaccines (post-BSV acquisition)
Trial Phases:Phase 2: 1
CORPORATE STRUCTURE
Subsidiaries:Bharat Serums and Vaccines Limited (100% acquired 2024), COPMED Research Centre (non-wholly owned subsidiary in Uttarakhand), Mediforce Research Centre (non-wholly owned subsidiary in Himachal Pradesh)
Key Partnerships:AstraZeneca - distribution partnership for Symbicort, Novartis, Takeda, Innovent Biologics - oncology collaboration (Sintilimab), Innov8 - real estate investment (January 2025)
COMPETITION
Position:Leader
Competitors:Emcure Pharmaceuticals, Sun Pharmaceutical, Lupin Limited, Cipla, Dr. Reddy's Laboratories, Aurobindo Pharma, Cadila Healthcare, Glenmark Pharmaceuticals
LEADERSHIP
Key Executives:
Ramesh Chand Juneja - Chairman & Wholetime Director
Rajeev Juneja - Vice Chairman & Managing Director
Sheetal Arora - Whole Time Director & Chief Executive Officer
Arjun Juneja - Chief Operating Officer
Satish Kumar Sharma - Whole-Time Director
Scientific Founders:Ramesh C. Juneja, Rajeev Juneja, Prem Kumar Arora
Board Members:Ramesh Chand Juneja (Chairman), Rajeev Juneja, Sheetal Arora, Tilokchand Punamchand Ostwal (Independent Director), Bharat Anand (Independent Director)
LINKS
Website:mankindpharma.com
LinkedIn:LinkedIn Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Mankind Pharma Limited and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Mankind Pharma Limited. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.